I am/have/had
I am looking for
Advanced Filters
Found 1231 clinical trials
Featured trial
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
As part of postremission consolidative therapy, the decision to proceed with hematopoietic stem cell transplantation is a recommendable regimen in ALL therapy. However, The recurrence rate is high after transplantation. Minimal Residual Disease (MRD) is an important factor affecting the effect of HSCT.
- 0 views
- 16 Mar, 2026
- 2 locations
